ZEPP
INSIDER SELLZepp Health Corp
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeZepp Health reported modest 6.9% revenue growth to $63.5M in Q2 2026 but faced widening losses and guided Q3 2026 revenue down 4-10% YoY to $68-73M, citing supply-chain constraints and weak macroeconomic conditions. Multiple sell-rating downgrades from Wall Street Zen and Weiss Ratings followed, with insider selling accelerating in late September as the stock traded near 52-week lows.
Red flags
- •Q3 2026 guidance implies 4-10% YoY revenue decline despite earlier growth trajectory
- •Widening net losses in Q2 2026 despite revenue growth
- •Multiple analyst downgrades to 'sell' rating (Wall Street Zen in August and September; Weiss Ratings reiteration)
- •Supply-chain bottlenecks and production ramp issues cited as near-term headwinds
- •Insider selling by Pengtao Yu totaling ~10,000 shares in late September at $4.09-$4.30 range
- •Stock trading near 52-week lows and below 200-day moving average
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).